ArticleProceedings of the National Academy of Sciences of the United States of America1997
Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 115 citations in OpenAlex.
- The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.International journal of molecular sciences · 2021Review
- Structural and functional characterization of a complex between the acidic transactivation domain of EBNA2 and the Tfb1/p62 subunit of TFIIH.PLoS pathogens · 2014Article
- CIITA and Its Dual Roles in MHC Gene Transcription.Frontiers in immunology · 2013Article
- Role of Sug1, a 19S proteasome ATPase, in the transcription of MHC I and the atypical MHC II molecules, HLA-DM and HLA-DO.Immunology letters · 2012Article
- Article
- Transcription factor effector domains.Sub-cellular biochemistry · 2011Article
- Novel functions for TAF7, a regulator of TAF1-independent transcription.The Journal of biological chemistry · 2010Article
- Nucleosome eviction from MHC class II promoters controls positioning of the transcription start site.Nucleic acids research · 2009Article
- Genetics and visceral leishmaniasis: of mice and man.Parasite immunology · 2009Review
- Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator.The Journal of biological chemistry · 2008Article
- Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan.PLoS genetics · 2007Article
- ZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcription.Molecular immunology · 2007Article
- Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.Journal of virology · 2005Article
- Article
- CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II.The EMBO journal · 2003Article
- Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.Molecular and cellular biology · 2003Article
- Novel mechanisms of class II major histocompatibility complex gene regulation.Immunologic research · 2003Review
- The class II transactivator requires brahma-related gene 1 to activate transcription of major histocompatibility complex class II genes.Molecular and cellular biology · 2002Article
- Impaired regulation of HLA-DR expression in human immunodeficiency virus-infected monocytes.Clinical and diagnostic laboratory immunology · 2002Review
- Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation.Molecular and cellular biology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.